{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Acute+Myeloid+Leukemia&page=5&q=relapsed+refractory+AML", "query": { "q": "relapsed refractory AML", "condition": "Acute Myeloid Leukemia", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 1016, "total_pages": 102, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Acute+Myeloid+Leukemia&page=6&q=relapsed+refractory+AML&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Acute+Myeloid+Leukemia&page=4&q=relapsed+refractory+AML&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-13T19:33:49.086Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03761069", "title": "Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia, Myeloid, Acute", "AML" ], "interventions": [ { "name": "PTC299", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PTC Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2018-10-29", "completion_date": "2021-12-28", "has_results": false, "last_update_posted_date": "2022-02-02", "last_synced_at": "2026-10-13T19:33:49.086Z", "location_count": 17, "location_summary": "Aurora, Colorado • New Haven, Connecticut • Detroit, Michigan + 14 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03761069" }, { "nct_id": "NCT04678401", "title": "IS-free Treg HaploHCT", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Stem Cell Transplant Complications", "Graft Vs Host Disease", "Myeloid Leukemia, Acute", "Myeloid Leukemia in Relapse (Disorder)", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "Radiation", "type": "RADIATION" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Thiotepa", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Treg-enriched donor cell", "type": "BIOLOGICAL" }, { "name": "Unmodified donor T Cell", "type": "BIOLOGICAL" }, { "name": "CD34+ Haplo Peripheral Blood Stem Cell", "type": "PROCEDURE" }, { "name": "Melphalan", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 30, "start_date": "2021-01-12", "completion_date": "2029-08-31", "has_results": false, "last_update_posted_date": "2025-10-20", "last_synced_at": "2026-10-13T19:33:49.086Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04678401" }, { "nct_id": "NCT00903422", "title": "Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myelodysplastic Syndrome" ], "interventions": [ { "name": "eltrombopag olamine", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 98, "start_date": "2009-05-14", "completion_date": "2013-12-05", "has_results": false, "last_update_posted_date": "2017-11-13", "last_synced_at": "2026-10-13T19:33:49.086Z", "location_count": 24, "location_summary": "Birmingham, Alabama • Santa Monica, California • Stanford, California + 20 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Santa Monica", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Coral Springs", "state": "Florida" }, { "city": "Lake Worth", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00903422" }, { "nct_id": "NCT06247787", "title": "A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Childhood Acute Myeloid Leukemia", "Recurrent Childhood Myelodysplastic Syndrome", "Recurrent Juvenile Myelomonocytic Leukemia", "Refractory Childhood Acute Myeloid Leukemia", "Refractory Childhood Myelodysplastic Syndrome", "Refractory Juvenile Myelomonocytic Leukemia" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Hydrocortisone Sodium Succinate", "type": "DRUG" }, { "name": "Imetelstat", "type": "BIOLOGICAL" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Lumbar Puncture", "type": "PROCEDURE" }, { "name": "Methotrexate", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "18 Years", "sex": "ALL", "summary": "1 Year to 18 Years" }, "enrollment_count": 36, "start_date": "2025-02-04", "completion_date": "2028-03-31", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-10-13T19:33:49.086Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Orange, California • San Francisco, California + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06247787" }, { "nct_id": "NCT02626338", "title": "Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed/Refractory Acute Myeloid Leukemia (AML)" ], "interventions": [ { "name": "Crenolanib", "type": "DRUG" }, { "name": "Mitoxantrone", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "Idarubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arog Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2016-02", "completion_date": "2018-02", "has_results": true, "last_update_posted_date": "2023-12-20", "last_synced_at": "2026-10-13T19:33:49.086Z", "location_count": 4, "location_summary": "Little Rock, Arkansas • Duarte, California • Dallas, Texas + 1 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02626338" }, { "nct_id": "NCT00012376", "title": "Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Blastic Phase Chronic Myelogenous Leukemia", "Chronic Myelomonocytic Leukemia", "Chronic Phase Chronic Myelogenous Leukemia", "Paroxysmal Nocturnal Hemoglobinuria", "Previously Treated Myelodysplastic Syndromes", "Recurrent Adult Acute Myeloid Leukemia", "Refractory Anemia", "Refractory Anemia With Ringed Sideroblasts", "Relapsing Chronic Myelogenous Leukemia", "Thrombocytopenia", "Untreated Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "bryostatin 1", "type": "DRUG" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2001-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-09", "last_synced_at": "2026-10-13T19:33:49.086Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00012376" }, { "nct_id": "NCT06382168", "title": "DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia, Myeloid, Acute" ], "interventions": [ { "name": "DFP-10917", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Delta-Fly Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2024-06-12", "completion_date": "2026-06-30", "has_results": false, "last_update_posted_date": "2025-09-03", "last_synced_at": "2026-10-13T19:33:49.086Z", "location_count": 4, "location_summary": "Orange, California • Winston-Salem, North Carolina • Burlington, Vermont + 1 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Winston-Salem", "state": "North Carolina" }, { "city": "Burlington", "state": "Vermont" }, { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06382168" }, { "nct_id": "NCT07320235", "title": "Imetelstat Combinations in Relapsed AML", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed Acute Myeloid Leukemia" ], "interventions": [ { "name": "Imetelstat", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Douglas Tremblay", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2026-01-02", "completion_date": "2035-06-15", "has_results": false, "last_update_posted_date": "2026-04-22", "last_synced_at": "2026-10-13T19:33:49.086Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07320235" }, { "nct_id": "NCT00919425", "title": "S9910, Collecting and Storing Blood and Bone Marrow Samples From Patients With Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Leukemia", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms" ], "interventions": [ { "name": "biologic sample preservation procedure", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1294, "start_date": "1999-04", "completion_date": "2012-01", "has_results": false, "last_update_posted_date": "2015-03-06", "last_synced_at": "2026-10-13T19:33:49.086Z", "location_count": 292, "location_summary": "Fort Smith, Arkansas • Berkeley, California • Burbank, California + 192 more", "locations": [ { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Berkeley", "state": "California" }, { "city": "Burbank", "state": "California" }, { "city": "Burlingame", "state": "California" }, { "city": "Fairfield", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00919425" }, { "nct_id": "NCT01207076", "title": "AHN-12 Biodistribution in Advanced Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myelogenous Leukemia", "Myelodysplastic Syndrome", "Acute Lymphoblastic Leukemia", "Chronic Myelogenous Leukemia" ], "interventions": [ { "name": "90Y-AHN-12", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 8, "start_date": "2013-12", "completion_date": "2014-07", "has_results": false, "last_update_posted_date": "2017-12-05", "last_synced_at": "2026-10-13T19:33:49.086Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01207076" } ] }